Stockscreener 앱 받기
101.87
2.16%
2.15
시간 외 거래:
101.95
0.08
+0.08%
전일 마감가:
$99.72
열려 있는:
$99.3
하루 거래량:
1.17M
Relative Volume:
1.18
시가총액:
$24.42B
수익:
$3.30B
순이익/손실:
$-501.07M
주가수익비율:
8.8288
EPS:
11.5384
순현금흐름:
$1.03B
1주 성능:
-6.31%
1개월 성능:
-8.86%
6개월 성능:
+12.43%
1년 성능:
+2.50%
1일 변동 폭
$98.25
$102.48
1주일 범위
$94.31
$115.93
52주 변동 폭
$76.53
$131.49
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BioNTech ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition - Benzinga
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE ADR rises Wednesday, still underperforms market - MarketWatch
A better buy-in window may exist right now for BioNTech SE ADR (BNTX) - SETE News
Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios - The Dwinnex
BioNTech SE ADR (BNTX)’s stock decline to 121.55 per share - US Post News
BioNTech SE ADR falls Monday, still outperforms market - MarketWatch
What is BioNTech SE ADR (BNTX) Stock Return on Shareholders’ Capital? - SETE News
BioNTech SE ADR (BNTX)’s results reveal risk - US Post News
Gaining Ground: BioNTech SE ADR (BNTX) Closes Higher at 119.93, Up 0.98 - The Dwinnex
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
BioNTech unveils AI advancements in immunotherapy - Investing.com
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BioNTech SE ADR (BNTX) can make a big difference with a little luck - SETE News
Wall Street SWOT: BioNTech stock shows promise amid oncology pipeline growth - Investing.com
Are Smart Investors Making the Right Decision? BioNTech SE ADR (BNTX) - SETE News
What Are You Thinking About Investing In BioNTech SE ADR (NASDAQ: BNTX) Stock? - Stocks Register
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
7.22%
자본화:
|
볼륨(24시간):